anti-PD-1/IL-2 fusion protein TEV-56278

A recombinant fusion protein composed of an antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to the cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration of anti-PD-1/IL-2 fusion protein TEV-56278, the antibody moiety targets and binds to PD-1 expressed on PD-1-expressing T cells in the tumor microenvironment (TME). The IL-2 moiety stimulates a local immune response and activates natural killer (NK) cells and cytotoxic T cells, which may enhance the activity of neoantigen specific T cells and potentiate T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.